Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    weill | Open Studies | "Acquired Immunodeficiency Syndrome"
Show Display Options
Rank Status Study
1 Recruiting Doxycycline for COPD in HIV-Infected Patients
Conditions: HIV;   Chronic Obstructive Pulmonary Disease (COPD);   Emphysema
Interventions: Drug: Doxycycline;   Drug: Placebo (sugar pill)
2 Recruiting HIV-related Accelerated Aging of the Airway Epithelium
Conditions: HIV;   COPD;   Chronic Obstructive Pulmonary Disease;   Smoking
Intervention:
3 Recruiting HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium
Conditions: HIV;   COPD;   Emphysema;   Smoking
Intervention:
4 Recruiting IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence
Condition: HIV Infection
Intervention:
5 Recruiting Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection
Condition: Tuberculosis
Interventions: Drug: Rifapentine (RPT);   Drug: Isoniazid (INH);   Dietary Supplement: Pyridoxine (vitamin B6)
6 Recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
7 Recruiting Enhanced Access to HIV Care for Drug Users in San Juan, Puerto Rico
Conditions: HIV;   AIDS;   Substance Abuse
Interventions: Behavioral: Enhanced HIV Care Access and Retention Intervention;   Behavioral: HIV Testing Campaign;   Behavioral: Treatment Re-engagement Campaign;   Behavioral: Patient Navigator Linkage to Care and Substance Abuse Treatment Team;   Behavioral: Mobile Care Clinic
8 Recruiting Integrase and Maraviroc Intensification for Neurocognitive Dysfunction (InMIND)
Condition: HIV Infections
Interventions: Drug: Placebo for maraviroc (MVC);   Drug: Placebo for dolutegravir (DTG);   Drug: Dolutegravir (DTG);   Drug: Maraviroc (MVC)
9 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
10 Recruiting Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Conditions: Anal Intraepithelial Neoplasia;   High-grade Squamous Intraepithelial Lesion;   HIV Infection
Interventions: Drug: imiquimod;   Drug: fluorouracil;   Other: questionnaire administration;   Other: laboratory biomarker analysis
11 Recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT);   Drug: Dasabuvir (DSV);   Drug: Ribavirin (RBV)
12 Recruiting Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive ART
Condition: HIV-1 Infection
Intervention: Drug: Sirolimus
13 Recruiting Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men
Condition: HIV Infections
Interventions: Drug: Cabotegravir tablets;   Drug: TDF/FTC tablets;   Drug: TDF/FTC placebo tablets;   Drug: CAB placebo tablets;   Drug: CAB LA;   Drug: Placebo for CAB LA
14 Recruiting Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
Conditions: HIV-1 Infection;   Hepatitis
Interventions: Drug: Ribavirin;   Drug: Sofosbuvir;   Drug: Ledipasvir/Sofosbuvir
15 Recruiting Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
Condition: HIV/AIDS
Interventions: Drug: BMS-663068;   Other: Placebo

Study has passed its completion date and status has not been verified in more than two years.